“…The first hormonal effect on cyclic GMP levels to be discovered was that produced by ACh in rat ventricle (George, Polson, O'Toole & Goldberg, 1970) and since then many investigators have demonstrated increases in cyclic GMP levels in response to cholinergic agents in a variety of cardiac preparations (Kuo, Lee, Reyes, Walton, Donnelly & Greengard, 1972; George, Ignarro, Paddock, White & Kadowitz, 1975;Watanabe & Besch, 1975;Gardner & Allen, 1976;Ghanbari & McCarl, 1976;Brown, Polson, Krzanowski & Wiggins, 1980;Lincoln & Keely, 1981; Dobson, 1981;Endoh, Maruyama & lijima, 1985). Furthermore, extracellular application of cyclic GMP or membrane-permeable derivatives of cyclic GMP often decrease contractile force (Wilkerson, Paddock & George, 1976;Trautwein & Trube, 1976;Nawarth, 1977;Kohlhardt & Haap, 1978;Linden & Brooker, 1979;Endoh & Yamashita, 1981;. It has been proposed that the negative inotropic effect of cyclic GMP, like that of ACh, is mediated by a decrease in ICa because cyclic GMP decreases 45Ca flux (Nawrath, 1977), shortens action potential duration (Trautwein, Taniguchi & Noma, 1982), and inhibits Ca2+-dependent action potentials (Kohlhardt & Haap, 1978;Bkaily & Sperelakis, 1985;Wahler & Sperelakis, 1985).…”